The TRANSCEND trial evaluated the efficacy and safety of setmelanotide for the treatment of acquired hypothalamic obesity.

Stifel analysts were bullish on the data, which showed a 16.5% drop in body-mass index among patients with damage to the ...

Shares of Rhythm Pharmaceuticals RYTM rallied 17.1% on Monday after the company announced that it has met the primary ...

Rhythm Pharma (RYTM) stock rises as lead asset setmelanotide succeeds in a Phase 3 trial for a rare obesity type, causing an ...

Wall Street is suddenly bullish on this under-the-radar player with FDA momentum and triple-digit upside potential.

While pharma giants Novo Nordisk and Eli Lilly may have a solid hold on the obesity arena, Rhythm Pharmaceuticals is looking ...

Patients with acquired hypothalamic obesity on setmelanotide therapy (n=81) achieved mean BMI change of -16.5% compared with +3.3% for placebo (n=39) at 52 weeks (p<0.0001) -- -- -19.2% placebo ...

Rhythm Pharmaceuticals (RYTM) announced topline results from the pivotal Phase 3 TRANSCEND trial evaluating setmelanotide, a melanocortin-4 ...